1-(4-(6-Chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-4-(thiophen-2-yl)butan-1-one

ID: ALA4776785

PubChem CID: 71523531

Max Phase: Preclinical

Molecular Formula: C18H19ClF3N3OS

Molecular Weight: 417.88

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(CCCc1cccs1)N1CCN(c2ccc(C(F)(F)F)c(Cl)n2)CC1

Standard InChI:  InChI=1S/C18H19ClF3N3OS/c19-17-14(18(20,21)22)6-7-15(23-17)24-8-10-25(11-9-24)16(26)5-1-3-13-4-2-12-27-13/h2,4,6-7,12H,1,3,5,8-11H2

Standard InChI Key:  WABCJNPZGIPCAE-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
   13.9583  -19.3319    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   14.6723  -19.7405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.6712  -18.9173    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   17.9576  -19.7447    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.3620  -20.4545    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.1751  -20.4571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.5898  -19.7515    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.1812  -19.0416    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3620  -19.0374    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.4112  -19.7552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.8165  -20.4689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.6378  -20.4727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.0473  -21.1864    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.8686  -21.1901    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3443  -21.8536    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   24.1268  -21.6005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.1305  -20.7791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3503  -20.5232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1392  -19.7463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.7277  -19.0326    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.9071  -19.0316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4971  -19.7436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.9096  -20.4581    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.7288  -20.4556    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.8230  -19.0453    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.2635  -20.4561    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   15.4985  -18.3238    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
  4  5  1  0
  4  9  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  7 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 14  2  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 19  1  0
  4 19  1  0
 22  2  1  0
 10 25  2  0
  2 26  1  0
 21 27  1  0
M  END

Associated Targets(non-human)

C2C12 (756 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 417.88Molecular Weight (Monoisotopic): 417.0889AlogP: 4.49#Rotatable Bonds: 5
Polar Surface Area: 36.44Molecular Species: NEUTRALHBA: 4HBD:
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 1.54CX LogP: 4.87CX LogD: 4.87
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.67Np Likeness Score: -2.13

References

1. Devine R,Kelada M,Leonard S,Martin DSD,Walsh JMD,Breen CJ,Driver RB,Kinsella GK,Findlay JBC,Stephens JC.  (2020)  Design, synthesis, and biological evaluation of aryl piperazines with potential as antidiabetic agents via the stimulation of glucose uptake and inhibition of NADH:ubiquinone oxidoreductase.,  202  [PMID:32645646] [10.1016/j.ejmech.2020.112416]

Source